Key Insights

Highlights

Success Rate

80% trial completion

Published Results

29 trials with published results (18%)

Research Maturity

68 completed trials (43% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

10.8%

17 terminated out of 158 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

8%

12 trials in Phase 3/4

Results Transparency

43%

29 of 68 completed with results

Key Signals

29 with results80% success17 terminated

Data Visualizations

Phase Distribution

105Total
Not Applicable (37)
P 1 (25)
P 2 (31)
P 3 (12)

Trial Status

Completed68
Recruiting31
Terminated17
Unknown17
Active Not Recruiting15
Not Yet Recruiting8

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 68 completed trials

Clinical Trials (158)

Showing 20 of 20 trials
NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT07029152Not ApplicableRecruitingPrimary

Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis

NCT07192055Not ApplicableRecruitingPrimary

Self-sampling to Optimize Anal Lesion Outcomes

NCT04287868Phase 1Active Not Recruiting

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

NCT07523152Not ApplicableNot Yet Recruiting

Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal Study

NCT05858736Phase 1Active Not Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

NCT04708470Phase 1Active Not Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

NCT04234113Phase 1Terminated

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

NCT05510908Completed

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

NCT06493019Phase 2RecruitingPrimary

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

NCT04094454Not ApplicableRecruitingPrimary

Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy

NCT04857528Recruiting

Detecting HPV DNA in Anal and Cervical Cancers

NCT05686226Phase 2Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT05639972Phase 1Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT07425054Phase 2Not Yet RecruitingPrimary

HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer

NCT04907643Not ApplicableRecruiting

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

NCT04432597Phase 1Active Not Recruiting

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

NCT06670495RecruitingPrimary

HPV Genotype Attribution and Disease Burden of Anal Cancer in China

NCT05551117Phase 2Terminated

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Scroll to load more

Research Network

Activity Timeline